
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc is poised for significant growth as it approaches several catalysts that may drive its stock value upward by over 100%, particularly through improvements in treatment efficacy and response durability in upcoming clinical trials. With forecasted sales of approximately $500-750 million anticipated from positive overall response rates (ORR) expected in the second half of 2025, the company stands to benefit from strong market positioning as it targets actionable oncogenic mutations. The potential for high M&A valuations, with estimates suggesting a 3-6 times upside based on comparable oncology acquisitions, further supports a robust outlook for the company’s financial health and stock performance.
Bears say
Black Diamond Therapeutics Inc. is facing significant skepticism about its pipeline, particularly regarding its drug silevertinib, which has resulted in a market capitalization of approximately $230 million reflecting low investor confidence. Concerns have been raised regarding its dosing and competitive positioning within the first-line EGFR-NCM patient population, with fears that upcoming clinical trials may reveal diminished efficacy when a broader representation of patient mutations is considered. Additionally, the mixed results of recent clinical updates have led to investor disappointment and may overshadow potential opportunities in other therapeutic areas, contributing to an overall negative outlook for the company’s stock performance.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares